BIOMAT Database Logo BIOMAT Database Logo

Chelation therapy in beta-thalassemia major. I. Intravenous and subcutaneous deferoxamine. 1978

J H Graziano, and A Markenson, and D R Miller, and H Chang, and M Bestak, and P Meyers, and P Pisciotto, and A Rifkind

UI MeSH Term Description Entries
D007263 Infusions, Parenteral The administration of liquid medication, nutrient, or other fluid through some other route than the alimentary canal, usually over minutes or hours, either by gravity flow or often by infusion pumping. Intra-Abdominal Infusions,Intraperitoneal Infusions,Parenteral Infusions,Peritoneal Infusions,Infusion, Intra-Abdominal,Infusion, Intraperitoneal,Infusion, Parenteral,Infusion, Peritoneal,Infusions, Intra-Abdominal,Infusions, Intraperitoneal,Infusions, Peritoneal,Intra Abdominal Infusions,Intra-Abdominal Infusion,Intraperitoneal Infusion,Parenteral Infusion,Peritoneal Infusion
D007501 Iron A metallic element with atomic symbol Fe, atomic number 26, and atomic weight 55.85. It is an essential constituent of HEMOGLOBINS; CYTOCHROMES; and IRON-BINDING PROTEINS. It plays a role in cellular redox reactions and in the transport of OXYGEN. Iron-56,Iron 56
D002648 Child A person 6 to 12 years of age. An individual 2 to 5 years old is CHILD, PRESCHOOL. Children
D002675 Child, Preschool A child between the ages of 2 and 5. Children, Preschool,Preschool Child,Preschool Children
D003676 Deferoxamine Natural product isolated from Streptomyces pilosus. It forms iron complexes and is used as a chelating agent, particularly in the mesylate form. Desferrioxamine,Deferoxamine B,Deferoxamine Mesilate,Deferoxamine Mesylate,Deferoxamine Methanesulfonate,Deferoximine,Deferrioxamine B,Desferal,Desferioximine,Desferrioxamine B,Desferrioxamine B Mesylate,Desferroxamine,Mesilate, Deferoxamine,Mesylate, Deferoxamine,Mesylate, Desferrioxamine B,Methanesulfonate, Deferoxamine
D004305 Dose-Response Relationship, Drug The relationship between the dose of an administered drug and the response of the organism to the drug. Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response
D004334 Drug Administration Schedule Time schedule for administration of a drug in order to achieve optimum effectiveness and convenience. Administration Schedule, Drug,Administration Schedules, Drug,Drug Administration Schedules,Schedule, Drug Administration,Schedules, Drug Administration
D005293 Ferritins Iron-containing proteins that are widely distributed in animals, plants, and microorganisms. Their major function is to store IRON in a nontoxic bioavailable form. Each ferritin molecule consists of ferric iron in a hollow protein shell (APOFERRITINS) made of 24 subunits of various sequences depending on the species and tissue types. Basic Isoferritin,Ferritin,Isoferritin,Isoferritin, Basic
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000293 Adolescent A person 13 to 18 years of age. Adolescence,Youth,Adolescents,Adolescents, Female,Adolescents, Male,Teenagers,Teens,Adolescent, Female,Adolescent, Male,Female Adolescent,Female Adolescents,Male Adolescent,Male Adolescents,Teen,Teenager,Youths

Related Publications

J H Graziano, and A Markenson, and D R Miller, and H Chang, and M Bestak, and P Meyers, and P Pisciotto, and A Rifkind
Management of beta-thalassemia major using transfusions and iron chelation with deferoxamine.
September 1988, Transfusion medicine reviews,
J H Graziano, and A Markenson, and D R Miller, and H Chang, and M Bestak, and P Meyers, and P Pisciotto, and A Rifkind
Combined subcutaneous and high-dose intravenous deferoxamine therapy of thalassemia.
January 1985, Annals of the New York Academy of Sciences,
J H Graziano, and A Markenson, and D R Miller, and H Chang, and M Bestak, and P Meyers, and P Pisciotto, and A Rifkind
Combined chelation therapy with deferasirox and deferoxamine in thalassemia.
February 2013, Blood cells, molecules & diseases,
J H Graziano, and A Markenson, and D R Miller, and H Chang, and M Bestak, and P Meyers, and P Pisciotto, and A Rifkind
[Evaluation of the efficacy of chelation therapy with deferoxamine in patients with thalassemia major].
May 1994, Medicina clinica,
J H Graziano, and A Markenson, and D R Miller, and H Chang, and M Bestak, and P Meyers, and P Pisciotto, and A Rifkind
High-dose intravenous chelation therapy with deferoxamine.
January 1989, Progress in clinical and biological research,
J H Graziano, and A Markenson, and D R Miller, and H Chang, and M Bestak, and P Meyers, and P Pisciotto, and A Rifkind
Myocardial iron loading in patients with thalassemia major on deferoxamine chelation.
January 2006, Journal of cardiovascular magnetic resonance : official journal of the Society for Cardiovascular Magnetic Resonance,
J H Graziano, and A Markenson, and D R Miller, and H Chang, and M Bestak, and P Meyers, and P Pisciotto, and A Rifkind
Effect of combined chelation therapy with deferiprone and deferoxamine on left ventricular diastolic function in adult beta-thalassemia major patients.
June 2010, Hemoglobin,
J H Graziano, and A Markenson, and D R Miller, and H Chang, and M Bestak, and P Meyers, and P Pisciotto, and A Rifkind
Renal dysfunction in patients with beta-thalassemia major receiving iron chelation therapy either with deferoxamine and deferiprone or with deferasirox.
January 2010, Acta haematologica,
J H Graziano, and A Markenson, and D R Miller, and H Chang, and M Bestak, and P Meyers, and P Pisciotto, and A Rifkind
Effects of combined deferiprone and deferoxamine chelation therapy on iron load indices in beta-thalassemia.
January 2008, Hemoglobin,
J H Graziano, and A Markenson, and D R Miller, and H Chang, and M Bestak, and P Meyers, and P Pisciotto, and A Rifkind
[Thalassemia major: chelating therapy with deferoxamine].
January 1985, Medicina,
Copied contents to your clipboard!